8-K: CVRx Appoints John Landry as New CFO

CVRx, Inc. announces the appointment of John Landry as its new Chief Financial Officer, succeeding Jared Oasheim, to bolster financial leadership for commercial growth.

Summary

• CVRx, Inc. has appointed John Landry as its new Chief Financial Officer (CFO), effective October 12, 2026.
• Mr. Landry will officially assume CFO responsibilities on the day following the company's Form 10-Q filing for the quarter ending September 30, 2026.
• He succeeds Jared Oasheim, who previously announced his intention to resign after his successor began.
• Mr. Landry brings over two decades of financial leadership experience in the medical device industry, including previous roles as CFO at Nyxoah SA and Vapotherm Inc.
• His compensation package includes an annual base salary of $500,000, a target cash incentive of 50% of base salary, and initial equity awards representing 0.80% of outstanding shares.
• The company also noted that Mr. Oasheim will remain for a transition period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating a strategic strengthening of the company's financial leadership with an experienced executive.

Positives

• Appointment of John Landry, an experienced CFO with a strong background in the medical device industry, to lead financial operations.
• Landry's experience in scaling high-growth medical device companies and managing capital markets is seen as valuable for CVRx's commercial expansion.
• The compensation package for Mr. Landry includes a base salary, incentive bonus, and significant equity awards, aligning his interests with shareholders.
• A smooth transition plan is in place with Jared Oasheim remaining for a period.

Negatives

• The departure of Jared Oasheim, who led the company through its IPO and helped build its financial foundation, represents a loss of institutional knowledge.
• The transition of CFO responsibilities is tied to the filing of the Form 10-Q, introducing a slight delay in full assumption of duties.

Risks

• Potential challenges in integrating a new CFO into the company's existing financial structure and culture.
• The company's reliance on the successful commercialization and scaling of Barostim, which requires effective financial management.
• The possibility of Mr. Landry forfeiting a pro-rated bonus from his previous employer if he resigns before the first anniversary of his hire date, which could impact his motivation if not managed.

Future Outlook

The appointment of John Landry as CFO is intended to support CVRx's commercial growth strategy, particularly in scaling the Barostim therapy and reaching more heart failure patients. His experience in building and financing high-growth medical device companies is expected to be instrumental.

Management Comments

• "John is exactly the kind of finance leader we need for this next chapter. Over the past two decades, he has played a key role in building and financing high growth medical device companies introducing novel therapies like Barostim. He is a hands-on operational leader who has significant commercial and capital markets experience, and who is well known within the investment community. Johns experience driving growth while managing expenses is particularly relevant as we scale Barostim and reach more heart failure patients."
• "I want to thank Jared for the significant impact he has had at the company since 2015. He led us through our IPO and helped build the financial foundation we stand on today. We're grateful for his contributions and wish him success in his next chapter."
• "Barostim is changing how physicians treat heart failure and the positive impact it is having on patients lives is what drew me to this role. I've spent most of my career in the medical device industry helping to build the infrastructure and operating discipline needed as companies scale their commercial efforts. Im excited to join the CVRx team and see a real opportunity to bring that same operating discipline to support the business as we execute our commercial growth strategy."

Industry Context

StockSavvy.ai notes that the appointment of a seasoned CFO is a critical step for commercial-stage medical device companies like CVRx, especially as they aim to scale their innovative therapies such as Barostim. This move aligns with industry trends where strong financial leadership is essential for navigating capital markets, managing growth, and achieving market penetration.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO is generally viewed positively, potentially leading to improved financial management and strategic execution, which could benefit shareholder value.
• Employees: The transition may bring new leadership and potentially new financial strategies, impacting departmental operations and reporting structures.
• Creditors: A stable and experienced financial leadership team can provide confidence in the company's ability to manage its debt and financial obligations.

Next Steps

• John Landry to commence employment on October 12, 2026.
• John Landry to assume CFO responsibilities on the day after CVRx files its Form 10-Q for the quarter ending September 30, 2026 (expected early November 2026).
• Jared Oasheim to remain with the company for a transition period.

Key Dates

Recommendation

The filing announces a standard executive transition for the CFO role, bringing in an experienced individual. While positive for long-term financial leadership, it does not contain new material financial results or strategic shifts that would immediately warrant a buy or sell recommendation. It is an expected event in the company's lifecycle.

Keywords

Chief Financial Officer, CFO Appointment, Medical Device, Neuromodulation, Cardiovascular Diseases, Barostim, Financial Leadership, Executive Transition